Preclinical studies of recombinant human interleukin-3 (rhlL-3) and granulocyte-macrophage colony-stimulating factor (rhGM-CSF) have shown enhancement of multilineage hematopoiesis when administered sequentiatly. This study was designed t o evaluate the safety, tolerability, and biologic effects of sequential administration of rhlL-3 and rhGM-CSF after marrow ablative cytotoxic therapy and autologous bone marrow transplantation (ABMT) for patients with malignant lymphoma. Thirty-seven patients (20 patients with non-Hodgkin's lymphoma and 17 patients with Hodgkin's disease) received one of four different treatment regimens before ABMT. Patients were entered in one of four study groups t o receive rhlL-3 (2.5 or 5.0 pglkglday) administered by subcutaneous injection for either 5 or 10 days starting 4 hours after the marrow infusion. Twenty-four hours after the last dose of rhlL-3, rhGM-CSF (250 pg/mz/d as a 2-hour intravenous infusion) administration was initiated. rhGM-CSF was administered daily until the absolute neutrophil count (ANC) was =1,5OO/pL for 3 consecutive days or until NTENSIVE CYTOTOXIC treatment combined with autologous bone marrow transplantation (ABMT) has been shown to result in prolonged relapse-free survival for a significant fraction of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD) who fail to respond to standard therapy.'.' Infection and bleeding complications associated with marrow ablative transplant therapy are major causes of morbidity and mortality for these patients. A recent clinical trial showed that recombinant human granulocytemacrophage colony-stimulating factor (rhGM-CSF) administered after ABMT significantly reduced the duration of profound granulocytopenia compared with p l a~e b o .~ Patients treated with rhGM-CSF had fewer infections, a reduced requirement for antibiotics, and a shorter duration of hospitalization. However, rhGM-CSF did not affect platelet or red blood cell (RBC) recovery.
Recombinant human interleukin-3 (rhIL-3) is a multilineage hematopoietic growth factor that plays an important role in the activation, differentiation, and proliferation of hematopoietic progenitor cells. Several studies using cultured human bone marrow (BM) have shown that rhIL-3 alone or combined either sequentially or simultaneously with rhGM-CSF stimulated the growth of both myeloid and megakaryocytic lineage^.^.^ In nonhuman primate studies, rhIL-3 enhanced myeloid and platelet recovery, reducing chemotherapy-induced severe neutropenia.' In other preclinical studies, the combination of rhIL-3 and rhGM-CSF was synergistic in stimulating both neutrophil and platelet production. The sequential administration of rhIL-3 followed by rhGM-CSF had the greatest effect on increasing peripheral leukocyte counts.8"' These observations suggest that rhIL-3 may expand an early hematopoietic progenitor cell population, enabling more effective differentiation into mature cells with rhGM-CSF, a 'later-acting'' hematopoietic growth factor."." I Blood, Vol 84, No 7 (October l), 1994: pp 2151-2157 day 21 posttransplant. The most frequent adverse events in the trial included nausea, fever, diarrhea, mucositis, vomiting, rash, edema, chills, abdominal pain, and tachycardia. Three patients were removed from the study because of chest, skeletal, and abdominal pain felt t o be probably related t o study drug. Four patients died during the study period because of complications unrelated t o either rhlL-3 or rhGM-CSF. The median time to recovery of neutrophils (ANC =500/pL) and platelets (platelet count 220,0001pL) was 14 and 15 days, respectively. There were fewer days of platelet transfusions than seen in historical control groups using rhGM-CSF, rhG-CSF, or rhlL-3 alone. In addition, there were fewer days of red blood cell transfusions compared with historical controls using no cytokines or rhGM-CSF. These data indicate that the sequential administration of rhlL-3 and rhGM-CSF after ABMT is safe and generally welltolerated and results in rapid recovery of multilineage hematopoiesis.
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rhIL-3 has been evaluated as a single agent after ABMT for lymphoid malignancies in two In both trials, there was a modest acceleration of neutrophil and platelet recovery compared with that found in patients who received no growth factor after transplantation. However, in comparison to patients who received rhGM-CSF in a phase 111 trial, there appeared to be no improvement in neutrophil or platelet recovery.'
Based on these observations, we conducted the first clinical trial to evaluate the safety, tolerability, and biologic effect of sequential rhIL-3 and rhGM-CSF administered to patients with malignant lymphoma treated with intensive cytotoxic therapy and ABMT.
MATERIALS AND METHODS

Patients.
Patients enrolled in this study had either NHL or HD determined by the investigator to be incurable with conventional treatment regimens. The following five centers participated in this trial: the Sammons Cancer Center, Baylor University Medical Center (Dallas, TX); University Ireland Cancer Center, Case Western Reserve University (Cleveland, OH); J. G. Brown Cancer Center, University of Louisville (Louisville, KY); Roswell Park Cancer Institute (Buffalo, NY); and Oklahoma Memorial Hospital (Oklahoma City, OK).
Eligible patients included male and female patients 18 years of age or older who had Kamofsky Performance Scores of >60%, anticipated life expectancies of 8 weeks or longer, no significant organ system dysfunction, and a BM biopsy with 225% cellularity and no histologic evidence of malignant cells at the time of marrow harvest. In addition, patients had adequate cardiovascular, pulmonary, hepatic, and renal function before participation in the trial.
Patients were excluded from the trial for the following reasons: previous treatment with rhIL-3 or GM-CSFnL-3 fusion protein; a platelet count less than 100,O00/pL or absolute neutrophil count (ANC) less than 1,2OO/pL at the time of marrow harvest; a neoplastic disease requiring treatment within the last 5 years other than NHL, HD, non-melanoma skin cancer, or cervical cancer; myelosuppressive chemotherapy within 4 weeks of BM harvest; pelvic radiation before the marrow harvest; administration of hematopoietic growth factor within 2 weeks before the BM harvest or within 2 weeks before the marrow transplant. Patients who had acquired immunodeficiency syndrome (AIDS), a positive test for human immunodeficiency virus (HIV), any form of active hepatitis, required treatment with systemic corticosteroids, or who had previously undergone marrow transplantation therapy were also excluded. All patients provided written informed consent and protocols were approved by the Institutional Review Board for human investigation at each institution.
Marrow harvest. BM cells were obtained using standard procedures and frozen in 10% dimeythyl sulfoxide using controlled-rate liquid nitrogen freezing.I4 Marrow cells were not purged in vitro. The minimal number of marrow cells in the marrow graft was 0.9 X 10' nucleated cellskg actual patient weight.
Cytokines. The rhIL-3 and rhGM-CSF (Leucomax) used in this study were provided by the Cytokine Development Unit of Sandoz Pharmaceuticals Corp (East Hanover, NJ). Both cytokines are nonglycosylated proteins produced in Escherichia coli. rhIL-3 was reconstituted with sterile water and administered intravenously or subcutaneously. rhGM-CSF was mixed with 50 mL of normal saline and 0.1% human serum albumin and administered as a 2-hour infusion.
Study design. This trial was a multicenter phase VI1 open-label dose-finding study. Patients underwent complete baseline evaluations before receiving treatment with one of the following treatment regimens: (l) etoposide (1,800 to 2,400 mglm'), cyclophosphamide (6,000 to 7,200 mglm'), and BCNU (400 to 600 ~n g / m~) '~, '~;
(2) etoposide (1,800 mg/m'), cyclophosphamide (6,840 mglm'), and total body radiation (1,000 cGy)"; ( 3 ) etoposide (2,400 mg/m'), cisplatin (200 mg/m'), and BCNU (600 mg/m')18; or (4) carboplatin (1,600 mg/m2) and thiotepa (900 m g /~n~) . '~ After completion of the treatment regimen, patients received an infusion of autologous marrow cells (day 0). Four hours later, patients received their first dose of rhIL-3. Patients received rhIL-3 in the following four study groups: group 1 received rhIL-3 at 2.5 pg/ kg/day for 5 days; group 2 received rhIL-3 at 2.5 pg/kg/d for 10 days; group 3 received rhIL-3 at 5.0 pgkg/d for 5 days; and group 4 received rhIL-3 at 5.0 pg/kg/d for 10 days.
Three patients were initially treated with the lowest dose of rhIL-3 (group 1). Subsequent groups of 3 patients were treated with the higher rhIL-3 doses (groups 2 through 4). depending on safety and tolerability. Subsequently, additional patients were entered into groups 1 through 3 to further assess safety, tolerability, and biologic activity.
Initially, 3 patients in group 1, 1 in group 2, and 1 in group 4 received rhIL-3 as a 2-hour intravenous infusion. To facilitate administration of rhIL-3, the protocol was subsequently amended and all additional patients received rhIL-3 subcutaneously.
Twenty-four hours after the last dose of rhIL-3, all patients received their first dose of rhGM-CSF (250 ,ugh2). rhGM-CSF was administered daily until the ANC was 2 1500/pL for 3 consecutive days or until day 27, whichever occurred first.
RBC transfusions were administered to maintain the hematocrit between 22 and 30. Platelet transfusions were administered to maintain a platelet count of 22O,OOO/pL. Patients were treated with broad spectrum antimicrobials when fever developed and the ANC decreased to less than 500/pL. Amphotericin B (0.5 to 1.0 pg/kg/d) was added if patients had persistent fever after 4 to 7 days of broad spectrum antimicrobial therapy.
Treatment monitoring. To assess toxicity and biologic activity of sequential rhIL-3 and rhGM-CSF, patients underwent daily assessments of symptoms and physical examinations while hospitalized and weekly after discharge. Laboratory studies, including a complete blood cell count (CBC), a white blood cell differential, a platelet count, and a reticulocyte count, were obtained at baseline, daily while in the hospital, and 2 or 3 times per week after discharge. Serum chemistries, a urinalysis, and a coagulation profile were performed at baseline and 2 or 3 times per week thereafter. Assessment of tumor response to treatment was generally performed 30 days after the BMT and was planned every 3 to 4 months thereafter for 1 year after transplant.
Adverse events. All adverse events, whether or not considered related to the administration of rhIL-3 and/or rhGM-CSF, were evaluated throughout the study. Adverse events included any new signs, symptoms, physical findings, or changes in baseline concurrent conditions. The severity of the adverse event and its relationship to the administration of rhIL-3 and/or GM-CSF were evaluated. Adverse events were graded by the clinical investigator as mild, moderate, or severe using toxicity parameters pooled from Eastern Cancer Oncology Group (ECOG), Northern California Oncology Group (NCOG), Southwest Oncology Group (SWOG), and National Cancer Insitute (NCI) toxicity parameters.
Statistical analysis. All reported adverse events were included in the overall incidence estimates, regardless of any relationship or causality assigned to the cytokines by the investigator.
Time-to-event outcomes were evaluated using life table techniques (Kaplan-Meier estimate). Because of the small number of patients in each rhIL-3 study group and because the treatment outcomes were similar among the study groups, data were pooled to estimate median times to platelet and neutrophil engraftment and time to hospital discharge. For the engraftment parameters, patients who did not have an ANC 2 1,50O/pL or a platelet count of >20,000/ pL during the period of observation were censored on the last day an ANC or platelet count was available. Patients who died were censored on the study day of their death for each of the time-toevent outcomes. There were too few patients to statistically compare the biologic activity of rhIL-3 and rhGM-CSF treatment among the study groups.
Medians and ranges were determined for the number of transfusion events and the number of units transfused. To meaningfully evaluate the total number of platelet units transfused, the number of units of apheresed platelets was converted to standard units by multiplying the number of apheresed units by 6.4.20
RESULTS
From April 1992 to January 1993, a total of 37 patients with refractory lymphoma were enrolled. Twenty patients SEQUENTIAL IL-3IGMCSF IN ABMT Table 1 . The Karnofsky performance score (KPS) listed in Table 1 was determined on day 0 after the cytotoxic treatment regimen was administered and ranged from 50% to 100%. Treatment regimens consisting of either high-dose etoposide, cyclophosphamide and BCNU; highdose etoposide, cyclophosphamide, and total body irradiation (TBI); high-dose etoposide, cisplatin, and BCNU; or high-dose carboplatin and thiotepa were administered to 16, 10, 9, and 2 patients, respectively. Safety and tolerability. Overall, the most common ( 2 5 0 % of patients) adverse events in the study were nausea (97%), fever (97%), diarrhea (92%), mucositis (83%), vomiting (78%), rash (75%), edema (72%), chills (a%), abdominal pain @g%), and tachycardia (50%). It was difficult to determine in every instance whether these events were related to underlying disease, to the transplantation procedure, or to the drugs used in the study. To assess the safety and tolerability of sequential rhIL-3 and rhGM-CSF and to determine dose-limiting toxicities, if any, the number and percentage of patients with at least one severe adverse event considered to be related or remotely related to study drug was examined. Overall, 22 patients (59%) had at least one severe adverse event secondary to any attribution. Eleven of 37 patients (30%) had at least one severe event considered by the investigator to be possibly or probably related to rhIL-3 and/or rhGM-CSF. Six of 14 patients (43%) in groups 3 and 4 (rhL-3 at 5.0 pgfkgfd for 5 or 10 days, respectively) had severe adverse events possibly or probably related to cytokines, in contrast to 5 of 23 patients (22%) in groups 1 and 2 (rhIL-3 at 2.5 pg/kg/d for 5 or 10 days, respectively). There was a total of 15 severe adverse events in the 11 patients; these events are listed in Table 2 .
Frequencies of unique severe events were also tabulated. For this evaluation, if a given event occurred more than once, it was counted as only one unique event. The highest frequency of severe events both overall and possibly or probably related to cytokines occurred in group 4 (rhIL-3 at 5.0 pgkgld for 10 days). Seven patients were removed from the study before day 42 post-ABMT because of a severe adverse event (3 patients) or death (4 patients). The 3 patients removed from the study because of an adverse event possibly related to cytokines had chest, skeletal, or abdominal pain at days 13, 13, and 19 post-ABMT, respectively. These 3 patients are among those listed in Table 2 . All 3 patients were receiving rhGM-CSF at the time they were removed from the study. Among the 4 patients who died during the study period, 1 patient died on day 6 because of sepsis associated with lymphomatous intestinal wall perforation; 1 patient died on day 8 because of respiratory distress and pseudomembranous enterocolitis; 1 patient died on day 9 because of multiorgan failure secondary to tumor lysis syndrome; and 1 patient died on day 12 secondary to cardiac and renal failure related to the cytotoxic treatment regimen. Table 3 lists the reasons for early patient withdrawal from the study. The patient who developed cardiac and renal failure had symptoms and signs of pulmonary edema before ABMT. However, the rhIL-3 was felt possibly to be responsible for the pulmonary edema by the clinician; consequently, pulmonary edema is listed in Table 2 .
An additional 7 patients died after ABMT. Six patients, all with advanced lymphoma before transplant, died of progressive lymphoma between 78 and 287 days after transplantation. One patient died of BCNU-related pulmonary fibrosis at day 88.
Biologic activity. The biologic activity of sequential rhIL-3 and rhGM-CSF after ABMT was assessed by examining granulocyte and platelet recovery, as well as platelet transfusion requirements. There were no differences in granulocyte and platelet recovery after ABMT for HD or NHL (data not shown). Therefore, blood count recovery data were pooled for analysis. The median day to engraftment of neutrophils after transplant, defined as a sustained ANC 2 100, 500, and l,OOO/pL, was 11, 14, and 16 days, respectively. The data for neutrophil recovery to =500/pL are shown in Fig 1. All patients experienced neutrophil recovery, except the 4 patients who died during the study period.
The day of platelet engraftment was defined as the first of 5 consecutive days of an untransfused platelet count that was 220,OoO/pL. The median time for a sustained platelet count 22O,OOO/pL was 15 days (Fig 1) .
At the end of the study (day 42), 8 patients had not achieved a sustained platelet count 220,0OO/pL; this includes the 4 patients who died during the study period and 4 additional patients who remained dependent on platelet transfusions beyond day 42. For the remaining 29 patients, the median number of days that platelet transfusions were administered was 5 days, with a range of l to 25 days. A median of 30 U of platelets was transfused (range, 6 to 174) over the course of the study. Thirty-three patients were alive and RBC transfusion-independent by day 42. The median number of days that RBC transfusions were administered was 4. The median number of packed RBC units transfused was 6.
The median number of days of hospitalization for all patients (n = 37) was 22.
Excluding the 4 patients who died before day 42, 33 patients were evaluated for serious infectious complications after transplantation. Five patients (15%) experienced bacteremia between day -5 and day 22. Four of these patients had bacteremia with gram-positive cocci and 1 patient had gram-negative bacteremia. There were no serious fungal or viral infections.
Twenty-one patients (57%) experienced a complete (12 patients) or partial (9 patients) response after transplantation when restaged by day 42. Seven patients had stable disease and 3 patients had progressive disease. Staging studies were not available on 2 patients and 4 patients died early, so their disease status was unknown. Currently, there are 26 patients (70%) who are alive between 10 and 19 months after transplantation.
DISCUSSION
The primary objective of this trial was to estimate the optimal dose and schedule of rhIL-3 and rhGM-CSF after ABMT. We selected four different rhIL-3 dose schedules followed by rhGM-CSF that were felt likely to be safe and tolerable for patients undergoing marrow transplantation. The dose and route of administration of rhGM-CSF in our trial was the same as that reported by others in ABMT for lymphoma except it was administered after an initial treatment with rhIL-3.3
There are abundant in vitro marrow culture and preclinical animal data indicating substantial enhancement of multilineage hematopoiesis with the sequential administration of rhIL-3 and rhGM-CSF.4311 The hematopoietic effect of the sequential combination of these cytokines presumably is related to enhanced proliferation of cellular elements early in the hematopoietic lineage by rhIL-3, followed by further proliferation and differentiation of hematopoietic progenitors by rhGM-CSF. The design of this trial attempts to take advantage of the hematologic effects of sequential rhIL-3 and rhGM-CSF.
Preliminary data are emerging from clinical studies of rhIL-3 administered to patients alone or in combination with rhGM-CSF after cytotoxic chemotherapy for neoplastic diseases. These studies suggest enhanced recovery of both neutrophil and platelet production without serious adverse ef- All four regimens of rhIL-3 followed by rhGM-CSF were reasonably well-tolerated, with no consistent toxicities attributable to rhIL-3. Only 3 patients were removed early from the trial because of skeletal, chest, or abdominal pain. These patients were receiving rhGM-CSF at the time these symptoms developed. Other clinical trials using rhIL-3 or rhGM-CSF after ABMT have reported such toxicities as low-grade fever, myalgias, headaches, skeletal pain, nausea, and diarrhea.'2.'3'27 Patients who receive high-dose cytotoxic therapy and ABMT commonly have similar symptoms and assigning a relationship to rhIL-3 and rhGM-CSF may not be possible. Nevertheless, 6 of 14 patients (43%) who received 5.0 pg/ kg/d of rhIL-3 had at least one severe adverse event considered by the investigator to be probably or possibly related to rhIL-3 and/or rhGM-CSF. However, this was true for only 5 of 23 patients (22%) who received the 2.5 pg/kg/d dose of rhIL-3. There were too few patients in the trial to determine statistical differences in frequency of severe adverse events between the rhIL-3 groups. BM recovery after ABMT was similar in all four sequential cytokine study groups. No patients have developed marrow failure with follow-up ranging between 9 and 16 months from transplant. Too few patients in this study were entered in each rhIL-3 study group to show statistically significant differences in hematopoietic recovery. However, to estimate the potential benefit of sequential rhIL-3hhGM-CSF after ABMT, marrow recovery data were pooled from all four rhIL-3 subgroups for purposes of comparison to published experience without cytokines and with rhGM-CSF, rhG-CSF, or rhIL-3 a10ne.3.'2*28.29 Table 4 compares the median day of neutrophil and platelet recovery after intensive cytotoxic therapy, ABMT, and treatment with sequential rhIL-3 50 and rhGM-CSF with the median day of neutrophil and platelet recovery when no cytokines are administered or treatment with rhGM-CSF, rhG-CSF or rhIL-3 alone is administered.
In our study, the median day to an ANC 2500/pL was 14, and to an ANC 2 l,OOO/pL was 16. This finding is similar to the granulocyte recovery after ABMT and rhG-CSF monotherapy and may be faster than that seen after rhGM-CSF or rhIL-3 alone. In addition, serious bacterial infections were uncommon in our trial and there were no systemic fungal or viral infections.
Platelet recovery after transplantation and combination cytokine therapy was prompt. The median time for a sustained platelet count 220,0OO/pL was 15 days after transplantation. Patients required a median of five platelet transfusions after marrow transplant. These data indicate substantial enhancement of thrombopoiesis after ABMT using sequential rhIL-3 and rhGM-CSF and represent significant hastening of platelet recovery compared with ABMT followed by rhGM-CSF, rhG-CSF, or rhIL-3 m~n o t h e r a p y .~~'~*~* *~~ Indeed, platelet recovery after ABMT and sequential rhIL-3 and For personal use only. on September 14, 2017. by guest www.bloodjournal.org From rhGM-CSF in this trial is comparable to that reported with rhG-CSF-primed peripheral blood progenitor cell transplantation after similar intensive cytotoxic therapy for lymph~ma.'~~'' Given that the number of hematopoietic progenitor cells in an autologous marrow graft are substantially fewer on average than obtained with collections of cytokine primed peripheral blood cells, platelet recovery after ABMT and treatment with sequential rhIL-3 and rhGM-CSF is especially impressive." RBC recovery using sequential rhIL-3 and rhGM-CSF may be enhanced compared with results seen with ABMT and no cytokine or rhGM-CSF monotherapy. The median number of units of RBCs transfused after transplantation in our study was 6, compared with 8 U after rhGM-CSF or 10 U with placebo.' However, more data with sequential rhIL-3hhGM-CSF are necessary before final judgement on RBC recovery can be made with certainty.
There has been no indication that the antitumor response seen with the transplant therapy has been abrogated in any way because of the administration of sequential rhIL-31 rhGM-CSF. However, further follow-up is necessary.
Sequential administration of rhIL-3 and rhGM-CSF after BM ablative treatment for lymphoma and ABMT appears to stimulate multilineage hematopoiesis. When compared with historical control studies, granulocyte and platelet recovery appear more rapid compared with ABMT followed by rhGM-CSF or rhIL-3 monotherapy. Platelet recovery appears more rapid compared with that seen with G-CSF after ABMT. Indeed, the platelet recovery seen with sequential rhIL-3 and rhGM-CSF is comparable to that reported after cytokine-primed peripheral blood progenitor cell trans-plantati~n.~"'' rhIL-3 treatment at 2.5 pgkgld may be better tolerated than 5.0 pg/kg/d; too few patients were treated for determination of statistical differences. It is likely that additional patients treated with a dose of 5.0 pg/kg/d of rhIL-3 sequentially with rhGM-CSF would result in significant unacceptable toxicity. Although there were no apparent differences in patient tolerability between the 5and 10-day schedule of rhIL-3 at 2.5 pg/kg/d, we feel that the longer rhIL-3 schedule may have greater potential to enhance trilineage hematopoiesis when combined with rhGM-CSF after ABMT. Longer follow-up will be required for assessment of the effects of sequential rhIL-3 and rhGM-CSF on the overall survival of patients who receive ABMT therapy for refractory lymphoma. A prospective randomized clinical trial to determine whether sequential rhL-3 and rhGM-CSF is better than rhGM-CSF alone after marrow transplantation is ongoing.
